Top Story Today
Vertex Bets $10 Billion That It's More Than a Cystic Fibrosis Company
Vertex just agreed to buy Crinetics Pharmaceuticals for $10 billion in cash, paying a 102% premium and making it the largest deal in the company's history. The target: a rare disease endocrinology company with one commercial drug (Palsonify, an oral treatment for acromegaly) and a pipeline Vertex says could hit $5 billion in peak annual sales. It's a bold diversification play from a company that built its empire on cystic fibrosis and now calls endocrinology its "fifth pillar." The deal is backstopped by $4.5 billion in fully committed bridge financing from two banks.
Why it matters: Vertex is doing what every dominant franchise eventually must: finding the next act. This deal signals that big biotech will pay enormous premiums for commercial-stage rare disease assets, and it reshapes the competitive landscape in endocrinology overnight.
Read more →Deals and M&A
J&J Drops $785 Million for the Option to Buy a Company Later at $2.58 Billion
J&J locked in an exclusive option to acquire Sail Biomedicines for $2.58 billion, putting $785 million down upfront (including a $465 million equity stake). Sail is building in vivo CAR-T technology that could reprogram immune cells inside the body using circular RNA and targeted nanoparticles. It's pharma's version of "try before you buy," and it's J&J's biggest bet yet that the immunology treatment model is about to change.
Read more →Gilead Pays $2.2 Billion for a Startup That Barely Existed Two Years Ago
Gilead acquired Ouro Medicines and its sole drug candidate, a BCMA-targeting T-cell engager for autoimmune diseases, for up to $2.175 billion. The clever twist: Galapagos is expected to cover half the bill while Gilead keeps worldwide commercial rights. It's Gilead's latest in a string of acquisitions as it races to build an autoimmune franchise alongside HIV and oncology.
Read more →Novartis Spent Years Dismissing ADCs, Then Paid $1.1 Billion for One
After publicly doubting antibody-drug conjugates, Novartis acquired UK startup Myricx Bio for up to $1.5 billion. The catch: Myricx's drugs haven't been tested in humans yet. The draw is a first-in-class payload chemistry (N-myristoyltransferase inhibitors) that could sidestep resistance problems plaguing existing ADCs. It's a platform bet, not a single-drug purchase, in the hottest space in oncology.
Read more →Clinical and Regulatory
The First Drug for 'Always Hungry' Disease Faces Post-Market Safety Questions
Seven deaths and over 100 serious adverse events have surfaced in post-marketing reports for Vykat XR, the only approved drug for the relentless hunger of Prader-Willi syndrome. Advocacy groups stopped short of calling for withdrawal but urged closer monitoring. Neurocrine says it sees no causal link; analysts still project $1 billion-plus in peak sales. The gap between clean trial data and messy real-world use is on full display.
Read more →A Lung Cancer Mutation That Stumped Every Drug May Finally Have Its Match
Zipalertinib plus chemotherapy hit its primary endpoint in the Phase 3 REZILIENT3 trial for EGFR exon 20 insertion NSCLC, one of the hardest-to-treat lung cancer subtypes. The independent safety board recommended unblinding the study early. Specific numbers are pending, but the oral pill's selectivity for mutant EGFR could offer a simpler alternative to existing IV-based regimens.
Read more →China Adds Guardrails to Its Clinical Trial Machine; the U.S. Tries to Speed Up
New Chinese GCP rules taking effect September 1 add formal data governance requirements, investigator accountability, and tougher ethics standards. Meanwhile, the FDA is embracing AI tools, real-world evidence, and adaptive trial designs. The two biggest drug markets are converging from opposite directions, and global pharma companies are caught navigating both.
Read more →Science and Industry Trends
CRISPR's Biggest Problem Isn't the Scissors, It's the Cells Doing the Repairs
Researchers identified specific genes, led by a troublemaker called TREX1, that actively sabotage CRISPR editing efficiency by degrading the DNA templates needed for precise repairs. The discovery explains why identical CRISPR protocols produce wildly different results across patients and cell types, and it opens the door to smarter patient screening and better-designed gene therapies.
Read more →Lilly Sues Six Companies for Selling Its Obesity Drug Before It's Even Approved
Eli Lilly filed six lawsuits against companies selling retatrutide, its triple-agonist obesity drug that hasn't received FDA approval yet. The company has flagged over 14,000 listings across 100-plus countries. Retatrutide delivered up to 30% weight loss in trials, making it a magnet for black market sellers, and a public health risk for buyers injecting unregulated peptides.
Read more →Novo Nordisk Makes AWS Its Preferred Cloud Partner, Opens Joint Drug Discovery Hub
Novo Nordisk named Amazon Web Services its preferred cloud and AI partner, launching a co-innovation hub in London where pharma scientists and AWS engineers will work side by side on drug target discovery. It's the latest move in pharma's cloud arms race, following Merck's $1 billion Google Cloud deal and 114 AI drug discovery partnerships announced in 2025 alone.
Read more →Three Biotech IPOs Raised Over $1.2 Billion in a Single Stretch
Braveheart Bio led the pack at $382.5 million in its IPO, followed by Kardigan at $400 million and Eikon Therapeutics at $381 million. After just 10 biotech IPOs in all of 2025, the window has swung wide open for late-stage companies with experienced teams and clear paths to commercialization.
Read more →